Objective-Genetic studies implicated upstream stimulatory factor 1 (USF1) in familial combined hyperlipidemia because the rs2073658 minor allele was associated with reduced risk of familial combined hyperlipidemia and related disorders. The molecular mechanisms whereby rs2073658 influences trait expression have remained elusive. Methods and Results-Plasma lipids, rs2073658 genotypes (N5372), and hepatic transcript levels (N596) of USF1 and genes involved in hepatic lipoprotein production were determined in obese subjects. The rs2073658 minor allele was associated with reduced plasma triglycerides (TGs) (P0.001), hepatic USF1 (P0.01), and microsomal TG transfer protein transcript levels (P0.05). Functional studies in human hepatocellular carcinoma cells showed that rs2073658 is located in a forkhead box A2 (FOXA2) binding site and that major allele constructs displayed higher transcriptional activity than minor allele constructs. Knockdown of FOXA2 reduced the activity of major, but not minor allele constructs. Furthermore, an interaction between hepatic FOXA2 transcript levels and rs2073658 minor allele carrier status on hepatic USF1 transcript levels was observed in vivo (P0.05). USF1 activated the transcription of FOXA2 and FOXA2 strongly activated the transcription of microsomal TG transfer protein. 
F amilial combined hyperlipidemia (FCHL), originally described in 1973, 1 is a common inherited lipoprotein disorder that predisposes affected individuals to premature coronary heart disease. The prevalence of FCHL is 20% in subjects with myocardial infarction before age 60, 2 and 1% to 2% in general Western populations. 3 Elevated plasma levels of very low-density lipoprotein (VLDL) and low-density lipoprotein are characteristic of the disorder. Frequently, plasma apolipoprotein (apo) B is elevated, and high-density lipoprotein (HDL) cholesterol is low. 2 Increased hepatic VLDL secretion is central to the pathogenesis of FCHL. 4 Chromosomal region 1q21-23 was identified as a main locus for FCHL in a Finnish population. 5 This result has been replicated in other populations. 6 Upstream stimulatory factor (USF) 1, located at chromosome 1q21, was classified as the first positionally cloned FCHL gene. 7 USF1, a member of the basic-helix-loop-helix leucine zipper family of transcription factors, is ubiquitously expressed and binds as a homo-or heterodimer with USF2 to E-boxes in regulatory gene regions. 8 USF1 target genes are numerous and include genes contributing to the regulation of glucose and lipid metabolism. 9 In the Finnish study, the more common allele at rs2073658, located in a highly conserved region of intron 7, showed the strongest associations with FCHL risk. Associations of rs2073658 (or single nucleotide polymorphisms [SNPs] in strong linkage disequilibrium with it) with FCHL or its trait components including elevated triglycerides (TG) have been confirmed in several studies. [10] [11] [12] [13] [14] [15] [16] rs2073658 has been linked to traits potentially affecting plasma lipid transport such as catecholamine-induced lipolysis, 17 antilipolytic insulin sensitivity, 18 and disrupted insulin induction of USF1 in skeletal muscle, 19 but the underlying molecular mechanisms are not understood.
FCHL has extensive overlap with components of the metabolic syndrome suggesting shared etiologic features, 20 and hepatic lipoprotein biosynthesis plays an important role in
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this and other forms of dyslipidemia. Although obesity is not a key feature of FCHL, we studied the effects of rs2073658 in livers of obese subjects known to be at increased risk for the metabolic syndrome 21 and describe a transcriptional circuit affected by rs2073658.
Methods study Populations
Study population 1 included 164 obese subjects undergoing a surgical weight-reducing procedure in Hallein Hospital between 2006 and 2010. Liver and adipose tissue biopsies, obtained during surgery, were collected in RNA-later (Ambion). Grading of fatty liver disease was determined by ultrasound as described. 22 Study population 2 included 178 obese subjects undergoing a surgical weight-reducing procedure in the same hospital between 1996 and 2000. Obese subjects from both populations were included if they had fasting blood glucose levels 7.0 mmol/L, no history of diabetes or use of glucose or lipid-lowering medication, and no weight changes 3% during the last 2 months and a body mass index (BMI) 33 kg/m 2 . Population 3 included 40-to 65-year-old male (N5626) and 45-to 70-year-old female (N5354) nonobese participants of the Salzburg Atherosclerosis Prevention Program in Subjects of High Individual Risk. Study objectives, recruitment procedures, and population characteristics have been detailed. 23 Exclusion criteria for the current study were BMI28 kg/m 2 , type 1 or type 2 diabetes mellitus, or a history of lipid-lowering medication. All study subjects provided informed consent, and study protocols were approved by the local ethics committee.
laboratory Analyses
Blood from all study subjects was collected after an overnight fast. In populations 1 and 2, plasma was separated by centrifugation at 4°C at the Hallein hospital. Samples were transported on ice to the Department of Laboratory Medicine, Salzburg. In population 1, glucose, cholesterol, TG, HDL cholesterol, apoAI, apoB, aspartate transaminase, alanine transaminase, -glutamyl transferase, alkaline phosphatase, ferritin, and high-sensitivity C-reactive protein were determined by routine laboratory procedures using the Hitachi modular platform and the respective reagents (Roche). Insulin was measured by immunoassay using the AxSYM and 2D01-20 reagent (Abbott). In population 2, plasma lipids were determined using a Hitachi 917 and the respective reagents (Roche). During both periods, the laboratory used strict internal quality control procedures and successfully participated in external surveillance programs. All analyses fulfilled the quality control criteria. Laboratory procedures used in the Salzburg Atherosclerosis Prevention Program in Subjects of High Individual Risk study have been detailed. 23 Insulin sensitivity/ resistance was estimated using the homeostasis model assessment insulin resistance index.
Gene expression
Total RNA from liver and adipose tissues was isolated using the RNeasy Mini Kit (Qiagen). RNA samples, stored at 280°C, were digested with DNase I (Promega) before reverse transcription. Transcript levels encoded by USF1 targeting exons 7 and 8 (Hs00273038_m1) or exons 9 and 10 (Hs00982876_m1), microsomal triglyceride transfer protein (MTTP) (Hs00165177_m1), apoB (APOB, Hs01071209_m1), forkhead box A2 (FOXA2) (Hs00232764_m1), and forkhead box A1 (FOXA1, Hs00270129_01) were quantified in duplicate using TaqMan gene expression assays (Applied Biosystems) listed in parentheses. Constitutively expressed acidic ribosomal protein RPLP0 mRNA was used as an internal standard for normalization of mRNA abundance. 24 Relative mRNA levels were calculated using the comparative threshold cycle method (DC T ) and the iCycler iQ Multicolour Real-Time polymerase chain reaction Detector ( Bio-Rad, Hercules, CA). The average interassay coefficient of variation of mRNA measurements ascertained by overlapping cDNA samples was 12%.
Genotyping
DNA was isolated from whole blood cells using the Generation Capture Column Kit (Gentra Systems) and the QIAmp Blood Kit (Qiagen) for population 1 and 2, respectively. Extracted DNA was stored at 220°C until analysis. The GA USF1 SNP (rs2073658) was typed using the TaqMan genotyping assay C_8757333_30 from Applied Biosystems. Correct typing was verified in 15% of the population 1 samples by sequencing.
Plasmids
The generation and description of reporter and expression constructs are detailed in the online-only Data Supplement.
electrophoretic Mobility shift Assays
Nuclear extracts were prepared from human hepatocellular carcinoma (HepG2) cells, and electrophoretic mobility shift assays were performed as described. 23 Sense strand sequences of oligonucleotides USF1-WT and USF1-MUT were 5-cgatAGCTACCATAAGTGGTCCTAATA CCT-3 and 5-cgatAGCTACCATAAATGGTCCTAATACCT-3, respectively. Overhangs are represented by lowercase letters, the putative FOXA2-binding site is shown in bold, and the polymorphic nucleotides are italics. Double-stranded 30-mers were prepared by annealing gel-purified sense and antisense oligonucleotides and the resulting single strand overhang was filled-in using [- 32 P]dATP and Klenow enzyme. Nuclear extracts (2 mg) were preincubated with binding buffer containing 1 mg of double-stranded poly(dI-dC) for 15 minutes at room temperature, 32 P-labeled major 30-mer (20 000 counts/min) was added, and the reaction mixture was incubated for 20 minutes on ice. For competition experiments, unlabeled double-stranded wild type and mutant competitor oligonucleotides were added during preincubation at 20-, 50-and 100-fold molar excess. For antibody-interference assays, nuclear extracts were preincubated with 1 mg of monoclonal FOXA2 antibody (sc-6554; Santa Cruz Biotechnology).
cell culture and Transfection studies
HepG2 cells were cultured as described. 25 Huh-7D 12 cells, obtained from Health Protection Agency Culture Collections, were cultured in DME (5796; Sigma) supplemented with 2 mmol/L l-glutamine and 1 mmol/L sodium pyruvate. Near-confluent cells were transfected with constant amounts of reporter constructs and 250 ng/well of FOXA2 or USF1 expression plasmids or their empty pcDNA6/ V5-His plasmid backbone using Lipofectamine 2000 reagent. pRL-TK (10 ng/well; Promega) was cotransfected as control. The transfection medium was replaced with fresh culture medium 12 hours later, and cells were harvested 24 hours after transfection. Firefly and renilla luciferase activities were measured in cell extracts using the Glomax Multi Detection System (Promega) and the Dual-Luciferase reporter assay system (Promega). Silencer select predesigned and validated small interference RNAs (siRNAs) targeting FOXA2 (5-GCUCCUCUCCAAAGAGGAUtt-3 and 5-GCCCUGAUGAUUCCGAGUUaa-3) were obtained from Ambion. FOXA2 siRNAs (50 nmol/L each) or negative control siRNA (50 nmol/L; Ambion) were transfected into HepG2 cells using Lipofectamine RNAiMAX (Invitrogen).
chromatin immunoprecipitation Assays
The chromatin Immunoprecipitation Kit ab500 (Abcam) was used. Crosslinking of 10 6 HepG2 cells, preparation of cell lysates, shearing of DNA to a median fragment size of 500 bp, and preparation of input DNA were performed as described. 25 After an overnight incubation with 4 mg of FOXA2-specific antibodies (sc-6554 and sc-20692; Santa Cruz Biotechnology) at 4°C, chromatin/DNA complexes were immunoprecipitated using protein A sepharose beads. After DNA purification, 5-AGACAGGGTTTCACCATGTTG-3 and 5-AGGACCACTTATGGTAGCTGG-3 were used as forward and reverse primers, respectively, to amplify a 130-bp fragment from the USF1 intron 7 encompassing rs2073658.
The proximal APOA1 promoter, used as a control for FOXA2 binding, was amplified using 5-ACTGAACCCTTGACCCCTG-3 and 5-TGGTCCTGGCAATGTGGAA-3 as the respective primers. Polymerase chain reaction products were separated by electrophoresis in 3% agarose gels and visualized by ethidium bromide staining. In addition, real-time polymerase chain reaction in the presence of Sybr-Green was performed for quantification using the DC T method and the 1% input reaction as reference.
Western Blotting
Immunoblotting was performed as described. 25 In brief, HepG2 cell extracts were prepared using the NE-PER kit (Pierce, Rockford, IL), and protein concentrations were determined using bicinchoninic acid (Pierce). We subjected equal amounts of extracts (20 mg) to sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by electroblotting. Blots of extracts were probed with specific polyclonal anti-FOXA2 antibody (sc-20692; Abcam) and a monoclonal mouse anti-GAPDH antibody (ab9484-200; Abcam). A horseradish peroxidase-conjugated antimouse antibody (ab9484-200; Abcam) and the SuperSignal West Substrate (Pierce) were used. Chemiluminescence was detected using a Kodak Imaging Station 2000 MM (Kodak).
confocal Microscopy
HepG2 cells were grown on collagen-coated coverslips. Cells were washed twice with PBS and treated with PBS containing 0.1% (v/v) Triton X-100 and 1% paraformaldehyde for 1 minute. After 3 quick washes with PBS, cells were fixed with 4% paraformaldehyde for 15 minutes. After 3 more washes with PBS and blocking with 10% horse serum for 30 minutes, cells were incubated with FOXA2 antibody (sc-6554; Santa Cruz Biotechnology) diluted 1:500 for 1 hour. After washing and blocking, cells were incubated with the secondary antibody (Invitrogen; antigoat Alexa-568), diluted 1:1000. All procedures were performed at room temperature. A confocal Laser Scanning Microscope (LSM715 Zeiss) equipped with an Axiocam digital camera was used.
statistical Analysis
Effects of rs2073658 were ascertained by ANOVA. Logarithmic transformations were used if the equal variance and normality assumptions of ANOVA were rejected. We adjusted measurements for effects of sex, age, and BMI. The proportions of interindividual variabilities of plasma TG and hepatic USF1 transcript levels, explained by rs2073658, were calculated using the R 2 from the ANOVA. An additional adjustment was made for population differences to determine the effect on TG in obese subjects from populations 1 and 2. Categorical data were analyzed by the  2 test. Allele frequencies were estimated by gene counting. Agreement with Hardy-Weinberg equilibrium was ascertained using a  2 goodnessof-fit test. Associations between log-transformed hepatic transcript levels were determined by linear regression analyses. To determine the effect of rs2073658 genotype or minor allele carrier status on the association between hepatic USF1 and FOXA2 transcript levels, we used multivariate regression analysis with log-transformed USF1 transcript level as dependent variable and BMI, age, sex, log-transformed FOXA2 transcript level, and rs2073658 genotype or carrier status as well as an interaction term between log-transformed FOXA2 transcript level and rs2073658 genotype or carrier status as independent variables. In transfection studies, ANOVA was used for comparisons of means and the Tukey honest significant difference test for post hoc comparisons. Graphs show meansSE of 4 to 9 independent experiments, each performed in quadruplicate, unless otherwise indicated. Fold induction is relative to promoter activity in cells transfected solely with the promoter luciferase constructs.
Reported P values are 2-tailed.
results
Genotypes associated with rs2073658 fulfilled HardyWeinberg expectations in all 3 populations. In population 1, the minor allele frequency was 0.299 and there was an association of rs2073658 genotypes with plasma TG (Table 1) , but no other plasma lipids was observed. Sex-specific analysis showed an association with TG in women (P50.0256), but not in the smaller population of men. No heterogeneity across sex was noted in the association with TG. Furthermore, average values for BMI were lower in heterozygous subjects. No associations of rs2073658 genotypes with liver function tests or liver steatosis were observed. In 96 study subjects, in whom liver biopsies were available, genotypes harboring the minor allele were associated with lower hepatic USF1 transcript levels ( Figure 1 ) in both the additive and dominant model (P0.01 or P0.003, respectively). After consideration of age, sex, and BMI, rs2073658 explained 8.9% and 6% of the variability of hepatic USF1 transcript abundance and plasma TG, respectively. USF1 mRNA levels in visceral and subcutaneous adipose tissues tended to increase with the number of minor alleles, but the effect was not significant ( Figure I in the online-only Data Supplement). USF2 transcript levels measured in liver and adipose tissue displayed no associations with rs2073658 (data not shown).
To further assess the relation of rs2073658 with plasma TG, we studied a second population of obese subjects recruited 10 years earlier. Neither the minor allele frequency (0.326) nor the distribution of genotypes differed from the respective values in population 1. The average age of patients in population 2 was slightly lower and population 2 comprised more women (both P0.05, Table II in the online-only Data Supplement). Furthermore, average values for TG and apoB were higher, whereas average values for HDL cholesterol and apoAI were lower (all P0.001). An association of rs2073568 minor allele carriers with TG was noted (P50.0277), whereas the association with genotypes was borderline significant (P50.0506, Table III in the online-only Data Supplement). As in population 1, no associations with apolipoproteins or other lipids were found. Because of the high variability in TG, we analyzed the distribution of rs2073658 genotypes in TG quartiles (Table IV in the online-only Data Supplement) and noted increasing frequencies of genotypes harboring 2 major alleles in going from low to high TG quartiles (P50.0136). Considering obese subjects from both populations and adjusting for the population effect, a P value of 0.0005 was obtained for the association between rs2073658 and plasma TG.
To study possible associations of rs2073658 in nonobese subjects, we typed 980 participants of the Salzburg Atherosclerosis Prevention Program in Subjects of High Individual Risk study, whose BMI was 28 kg/m 2 . The minor allele frequency (0.298) and the distribution of genotypes did not differ from the respective values in the combined obese populations. In nonobese subjects, only an association of rs2073658 with apoAI in the dominant model was observed (Table V in the online-only Data Supplement). Sex-specific analyses revealed borderline lower plasma TG in male carriers of the minor allele and higher apoAI and HDL cholesterol levels in female carriers of the minor alleles (data not shown). These results suggested that subtle effects of rs2073658 on lipid metabolism may have been present in our nonobese study group.
Earlier studies prompted the hypothesis that rs2073658 influences transcription from an alternative promoter located in intron 7.
7,26 As a result, variable amounts of putative transcripts lacking exons 1 to 7 would be generated. To test this hypothesis, we compared the USF1 mRNA levels measured by real-time polymerase chain reaction methods using primers targeting exons 7 and 8 or exons 11 and 12, respectively.
In liver biopsies from 23 subjects homozygous for the major allele and 28 minor allele carriers, the ratios of amplification products obtained with the 2 primer pairs did not differ (1.110.07 versus 1.040.05, meanSE, P50.35). Similar results were obtained in adipose tissue samples. These data strongly argued against the hypothesis that rs2073658 influences mRNA initiation from a putative alternative transcription start site in intron 7.
Previous sequencing studies of USF1 failed to identify any common SNP altering the coding sequence. 12, 27 Our in silico analyses showed that rs3737787, located in the 3-untranslated region, and 2 other SNPs, located in introns 3 and 6, were in perfect linkage disequilibrium with rs2073658. 28 Unlike rs2073658, these SNPs are not conserved nor predicted to alter transcription factor binding sites. 29 We also interrogated the sequence harboring rs3737787 for possible miRNA binding, thereby possibly influencing USF1 expression. Using 2 different human miRNA search engines (www.targetscan.org, release 6.0, November 2011 and www.mirbase.org, release 18, November 2011), we found only incomplete homologies to 2 miRNAs (miR-4657 and miR-148a/b) that seemed unlikely to play a role in USF1 expression. We therefore focused on rs2073658 and suspected that it might be located in a cis-regulatory element affecting hepatic USF1 transcription. Indeed, a 6-bp sequence harboring rs2073658 showed homology with the consensus core sequence for FOXA2 binding. In electrophoretic mobility shift assays using HepG2 nuclear extracts and bandshift probes containing the rs2073658 major or minor nucleotides, we observed specific DNA-protein complexes. Importantly, the unlabeled major allele probe was more effective than the minor allele probe in competing with the labeled major (Figure 2A ) or minor allele probes (not shown). In antibody interference assays, formation of DNA-protein complexes was inhibited by antibodies directed against FOXA2. To verify binding of FOXA2 to the respective gene segment in hepatocytes, we used chromatin immunoprecipitation assays. The region encompassing rs2073658 was readily amplified from HepG2 DNA immunoprecipitated with 2 different anti-FOXA2 antibodies ( Figure  2B) . Similarly, the bona fide FOXA2-binding site in the proximal APOA1 promoter, 30 serving as control, was amplified from such immunoprecipitated DNA.
To ascertain effects of rs2073658 on USF1 transcription, constructs containing 3 copies of the major or minor allele FOXA2-binding sequences downstream of a reporter gene driven by the USF1 promoter were transfected into HepG2 cells. Major allele repeat constructs displayed increased reporter gene activity compared with minor allele repeat constructs or promoter constructs without intron 7 sequences (P0.001). Major or minor allele repeats had no effect in promoter-less constructs ( Figure 2C ). Unexpectedly, FOXA2 expression plasmids did not alter the transcriptional activity of any construct, suggesting that FOXA2 was not limiting in HepG2 cells. Indeed, both FOXA2 mRNA and protein levels were 4-fold higher in HepG2 cells than in liver biopsies, but USF1 transcript abundance in HepG2 cells was 20-fold lower in comparison with liver biopsies ( Figure IIA and IIB in the online-only Data Supplement). The great majority of FOXA2 localized to cell nuclei, suggesting its transcriptional competence ( Figure IIC in the online-only Data Supplement). We therefore performed knockdown experiments by transiently transfecting HepG2 cells with 2 siRNAs targeting FOXA2. In comparison with mock-transfected controls, both FOXA2 mRNA and nuclear protein levels were reduced by 50% in FOXA2 siRNA-transfected cells ( Figure IID and IIE in the online-only Data Supplement). Knockdown of FOXA2 diminished the reporter gene activity of constructs containing the USF1 promoter along with major allele repeats (P0.002), whereas the reduction in the transcriptional activities of promoter constructs with or without minor allele repeats was not significant ( Figure 2C ).
To substantiate these results, we performed transient transfection studies in the well-differentiated hepatocyte-derived cellular carcinoma cell line Huh-7D 12. Compared with the respective expression levels in human liver biopsies, FOXA2 mRNA levels were 4-fold higher, while USF1 mRNA levels Figure 2 . rs2073658 is located in a forkhead box A2 (FOXA2) enhancer site affecting upstream stimulatory factor 1 (USF1) transcription. A, Electrophoretic mobility shift assays with nuclear extracts (Ne) prepared from human hepatocellular carcinoma (HepG2) cells. Extracts were incubated with 32 P-labeled, 30 bp double-stranded oligonucleotides corresponding to the wild-type (major) allele. Competition studies (Comp) included increasing concentrations of double-stranded wild-type (Wt) and variant or minor (Var) oligonucleotides. For antibody-interference assays, nuclear extracts were preincubated with 1 µg of monoclonal FOXA2 antibody (Ab) for 1 hour at 4°C. B, Chromatin was isolated from HepG2 cells, and a 130-bp fragment of USF1 intron 7 encompassing rs2073658 was amplified from DNA immunoprecipitated by 2 different anti-FOXA2 antibodies (Ab1, Ab2). The bona fide FOXA2-binding site in the APOA1 promoter served as control. As positive and negative controls, 1% of input DNA (Input) and the no-antibody precipitation reaction (No ab) were included; Neg refers to polymerase chain reaction (PCR) control without DNA. C, USF1 promoter reporter constructs with or without 3 repeats of the putative wild-type (major allele) or variant (minor allele) FOXA2-binding site downstream of the reporter gene were transiently transfected into HepG2 cells (black columns). Cotransfections with FOXA2 expression plasmids or FOXA2-specific small interference RNA are shown by gray or white columns, respectively. Cells were harvested 24 hours after transfection. USF1 promoter-driven luciferase levels were standardized to pRL-TK-driven renilla luciferase as a transfection control. The relative luciferase activity of the USF1 promoter reporter construct was set to 1. Columns (bars) are means (SE) of 5 to 9 experiments, each performed in quadruplicates; 11 refers to the transcriptional start site.
were only slightly lower ( Figure IIA and IIB in the online-only Data Supplement). Hence, Huh-7D 12 cells reflected the USF1/FOXA2 transcript ratio in human samples much more than HepG2 cells. Transcriptional activities of USF1 promoter constructs harboring major or minor allele repeats exceeded the activity of promoter constructs without repeats (Figure 3) . In contrast to HepG2 cells, USF1 promoter constructs were activated by FOXA2 (P0.001) in Huh-7D 12 cells.
Importantly, in cells cotransfected with FOXA2 expression plasmids, transcriptional activity of the promoter construct harboring major allele repeats was greater in comparison with the promoter construct containing minor allele repeats (P50.01) or the promoter construct without repeats (P0.01). Taken together, these data indicate that rs2073658 is located in a FOXA2 enhancer site and that the minor allele reduces binding of and transcriptional activation by FOXA2.
To gain in vivo evidence for a role of FOXA2 in USF1 mRNA expression, we measured FOXA2 transcripts in liver biopsies and noted a strong correlation between USF1 and FOXA2 transcript levels (R50.4367, P0.0001). Interestingly, the slope of the regression line decreased in going from subjects harboring 2 major alleles to minor allele carriers ( Figure 4A and 4B) . Age, sex, BMI, rs2073658 carrier status, and FOXA2 transcript levels explained 24.0% of the variance in USF1 transcript levels. Allowing for an interaction between FOXA2 transcripts and rs2073658 carrier status increased the proportion of the explained variance to 27.2% (P50.028; Figure 4C ). An analysis using the rs2073658 genotype instead of its carrier status also showed the interaction of FOXA2 transcript level and genotype (P50.0488; Figure III in the online-only Data Supplement) Thus, the in vivo data are consistent with the in vitro effect of rs2073658 on FOXA2-mediated transcriptional activation of USF1. As FOXA family members may bind to similar DNA sequences, 31 we measured FOXA1 transcripts in liver biopsies, but found no correlation with USF1 mRNA levels (R50.1300, N585, NS).
Because of the strong correlation between FOXA2 and USF1 transcript levels, we asked whether USF1 influences FOXA2 transcription in a hepatocellular environment. In transiently transfected HepG2 cells, cotransfection of USF1 expression plasmids activated the FOXA2 promoter, extending from 21172 to 1149 relative to the transcriptional start site ( Figure 5A, upper panel) . Deletion of the distal 29 Transcription of constructs containing the 4 upstream, but devoid of the 2 putative downstream binding sites was not activated by USF1 ( Figure 5A, middle) , and mutagenesis of each of the upstream E-boxes had no effect on the transcriptional activation by USF1 (data not shown). However, mutation of an atypical USF1-binding site located near the transcriptional start site abrogated activation by USF1 ( Figure 5A, bottom) . Hence, rs2073658 influences the strength of a feed-forward loop that comprises activation of USF1 transcription by FOXA2 and activation of FOXA2 transcription by USF1.
To determine possible mechanism(s) linking rs2073658 to plasma TG, we measured hepatic MTTP and APOB transcript levels. MTTP, but not APOB transcript abundance decreased with the number of rs2073658 minor alleles (P50.021; Table 2 ). MTTP transcript levels were moderately associated with USF1 (R50.250, P50.015), but strongly with FOXA2 transcript levels (R50.439, P0.0001). Furthermore, the USF1 expression plasmid did not alter the activity of the MTTP promoter (data not shown), whereas FOXA2 knockdown reduced the activity of such promoter constructs ( Figure  5B, top) . Promoter truncation by 700 bp increased its activity, but maintained the effect of FOXA2 knockdown. Site-directed mutagenesis of each of 2 putative FOXA2-binding sites identified the more proximal element as the functional site ( Figure  5B , bottom). 
discussion
Owing to its associations with FCHL and related metabolic disorders, rs2073658 has become the focus of intensive research, but the molecular mechanisms linking this polymorphism to trait expression have not been clarified. Here, we identified a transcriptional circuitry whereby rs2073658 likely influences hepatic TG secretion ( Figure 6 ). Our studies in 2 populations of obese subjects revealed associations of rs2073658 with plasma TG. The marked differences in plasma lipids and apolipoproteins between the obese populations are likely to reflect the more stringent criteria for bariatric surgery in earlier years, an increase in lifestyle changes in recent years, and the fact that most of the population 1 patients were seen by a physician 3 to 6 months before surgery to treat major metabolic abnormalities including diabetes mellitus and hyperlipidemias. In the third population, only a borderline significant association of rs2073658 carrier status with plasma TG was observed in men, suggesting that obesity is 1 of the factors that may influence the penetrance of rs2073658 alleles. Nevertheless, the discrete effects of rs2073658 on apoAI and HDL cholesterol, observed in nonobese women, are not inconsistent with a role of USF1 alleles in plasma TG. HDL cholesterol shows strong inverse associations with plasma TG and is a powerful predictor of postprandial triglyceride metabolism. 32 A cis-regulatory element is expected to influence transcript levels in the steady state and in response to physiological stimuli. Indeed, subtle allelic imbalances have been reported recently. Insulin induced USF1 mRNA levels in skeletal muscle biopsies from subjects homozygous for the nonrisk allele, but not from risk allele carriers. In addition, the risk allele was expressed at 20% lower levels than the nonrisk allele in adipose tissue. 19 The latter result is consistent with our adipose tissue data showing a trend for increased USF1 transcript levels in nonrisk allele carriers. In contrast, the nonrisk allele was associated with reduced hepatic USF1 transcript levels. FOXA2 which is not expressed in human adipose tissue (data not shown) may, at least in part, explain the opposing tissue-specific effects of rs2073658. Our results in liver are supported by studies in the F2 intercross, derived from the inbred mouse strains C57BL/6J and C3H/HeJ on an apoE null background. 33 Like obesity in our study subjects, the apoE null background in mice is conducive for plasma TG elevations. Hepatic USF1 transcript levels are under strong cis-regulation with 1.5-fold higher levels in mice homozygous for the C3H alleles (at the marker nearest USF1) compared with mice homozygous for the B6 alleles. Importantly, this mouse model recapitulates multiple metabolic traits, 33 and genotypes with increased hepatic USF1 transcript levels display elevated levels of cholesterol, TG, glucose, and insulin. 34 Previous transcriptional and mobility shift studies suggested that rs2073658 is located in a cis-regulatory site, but failed to identify differences between major and minor alleles. 7, 19 Hence, rs2073658 was hypothesized to influence activation of an alternative promoter in intron 7.
26 As a result, variable amounts of truncated proteins with dominant negative effects would be generated. We addressed this hypothesis, but did not detect associations between rs2073658 genotypes and the ratios of transcripts with or without exon 7. Thus, our own studies in liver and studies by others in adipose tissue 27 argue against this hypothesis. Rather, we observed allelic differences in competitive mobility shift assays and transient transfection studies of HepG2 cells. Importantly, the in vivo data showing an interaction of FOXA2 transcript abundance and rs2073658 carrier status on USF1 transcript levels are entirely consistent with our in vitro results.
In mature mice, FOXA2 increased VLDL secretion by activating hepatic MTTP expression. 35 MTTP transfers TG, phospholipids, and cholesteryl ester and is an essential chaperone for the assembly of apoB-containing lipoproteins. 36 Defective MTTP activity causes abetalipoproteinemia in humans, 37 and genetic ablation of MTTP in mice abolishes VLDL secretion, 38 while its overexpression results in increased secretion of apoB and VLDL. 39 The associations of rs2073658 with hepatic MTTP, but not APOB transcript levels therefore suggest that USF1 variants may influence TG secretion by affecting MTTP expression.
Insulin resistance is a central feature of the metabolic syndrome and is frequently encountered in FCHL. Insulin inhibits VLDL secretion, and impaired inhibition of VLDL secretion by insulin is thought to contribute to hypertriglyceridemia of insulin resistance. 40, 41 Insulin induces Akt-mediated phosphorylation of FOXA2 that results in its inactivation and nuclear exclusion. 42 Consequently, reduced MTTP expression has been implicated in the insulin-induced inhibition of VLDL secretion in the postprandial state. 35 However, higher levels of insulin were required for nuclear exclusion of FOXA2 in hepatocytes from insulin-resistant compared with insulin-sensitive mice. 43 Interestingly, the effect of rs2073658 on USF1 transcript levels and its interaction with FOXA2 transcript abundance were maintained after adjustment for homeostasis model assessment insulin resistance index. Hence, the molecular mechanisms Figure 6 . Intronic upstream stimulatory factor 1 (USF1) polymorphism and proposed transcriptional scenario modifying hepatic triglyceride (TG) secretion. rs2073658 is located in a forkhead box A2 (FOXA2) enhancer site that activates USF1 transcription. As USF1 transactivates FOXA2 transcription, a feed-forward loop is generated. The rs2073658 variant (minor) allele (Var) binds FOXA2 and transactivates USF1 transcription less efficiently than the wild-type (major) allele (Wt). As a result, the strength of the amplification loop is reduced, fewer FOXA2 transcripts are generated, less microsomal triglyceride transfer protein (MTTP) is produced, and hepatic TG secretion is limited.
described here might contribute to the fasting and postprandial hypertriglyceridemia of insulin resistance.
As MTTP is rate limiting in hepatic lipoprotein assembly and secretion, inhibition of MTTP frequently causes liver steatosis. 36 However, we did not observe an effect of rs2073658 on liver enzyme activities or the extent of hepatic steatosis. Thus, a reduction in hepatic TG secretion may be balanced by decreased hepatic TG synthesis or increased -oxidation. Clearly, a more detailed analysis is necessary to determine the mechanisms underlying the protection from hepatic TG retention.
Despite strong supporting evidence from in vitro data, our in vivo results require cautious interpretation. First, their relevance might be restricted to the obese population. Second, according to data from 1000 genomes, 3 other SNPs are in perfect linkage disequilibrium with rs2073658. 28 However, none of these SNPs are conserved, would be predicted to influence transcription factor binding, would likely be targeted by miRNA. Furthermore, 44 additional SNPs display strong linkage with rs2073658 (R 2 0.8). Some of these SNPs are located in adjacent genes that might affect phenotypes. Third, associations of USF1 SNPs with plasma lipid levels have not been replicated in all populations. 44 Fourth, to our knowledge, the USF1 locus has not been associated with lipid-related phenotypes in genome-wide association studies. However, several of the positive studies were conducted in populations ascertained for cardiovascular risk or lipid phenotypes. Hence, the penetrance of USF1 variants may vary with the genetic background and factors related to plasma lipid transport.
In conclusion, we deduced a molecular mechanism whereby rs2073658 protects from increased plasma TG. The pathway described does not preclude additional mechanism(s) that influence plasma lipid transport and may be modulated by rs2073658 or SNPs in linkage disequilibrium with it.
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